Lentiviral Vector Transduction Optimization for HSPCs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in efficiently transducing hematopoietic stem and progenitor cells, leading to low vector copy numbers and suboptimal therapeutic efficacy, which increases costs and safety concerns due to the need for high vector doses and toxic adjuvants.
Innovation Solution
The development of gene therapies that involve transducing hematopoietic stem and progenitor cells with lentiviral vectors at optimized multiplicities of infection (MOI) and vector copy numbers, achieving high transduction efficiency and viability, using agents like staurosporine and prostaglandin EP receptor signaling enhancers to improve transduction efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high vector doses are used to improve transduction efficiency, then the percentage of transduced cells increases, but toxic adjuvants and safety concerns increase
Solution Approach 1:
The patent optimizes the multiplicity of infection (MOI) parameter to achieve high transduction efficiency without requiring toxic adjuvants. By carefully controlling the vector dose and using lentiviral vectors with optimized transduction parameters, the method achieves effective gene delivery to hematopoietic stem and progenitor cells while avoiding the need for polybrene or other toxic enhancement agents
Solution Approach 2:
The patent uses a single-use, optimized lentiviral vector protocol that eliminates the need for repeated exposure to toxic adjuvants. The method achieves effective transduction in a single step with controlled MOI, avoiding cumulative toxicity from multiple rounds of transduction with adjuvant enhancement
2Productivity
If high vector doses are used to increase transduction efficiency, then more cells are transduced, but costs increase
Solution Approach 1:
The patent optimizes the multiplicity of infection (MOI) to achieve cost-effective transduction. By controlling the vector dose within an optimized range and using lentiviral vectors with enhanced transduction properties, the method achieves high transduction efficiency without requiring excessive vector quantities, thereby reducing manufacturing costs
3Ease of manufacture
If conventional transduction methods are used, then the process is simple, but vector copy numbers are low and therapeutic efficacy is suboptimal
Solution Approach 1:
The patent optimizes key transduction parameters including multiplicity of infection (MOI), incubation time, and cell density to achieve high vector copy numbers. The method uses lentiviral vectors with optimized transduction properties and controls cultural conditions to maximize gene delivery efficiency while maintaining a relatively simple procedural framework
Solution Approach 2:
The patent prepares hematopoietic stem and progenitor cells in advance by optimizing their cultural conditions and physiological state prior to transduction. This preliminary preparation enhances cell receptivity to viral vectors, enabling efficient transduction with optimized MOI without requiring complex procedural modifications
4Productivity
If high multiplicity of infection is used to increase transduction efficiency, then more cells are transduced, but cell viability may be compromised
Solution Approach 1:
The patent optimizes the multiplicity of infection (MOI) to achieve an optimal balance between transduction efficiency and cell viability. By controlling the vector dose within an optimized range and using lentiviral vectors with improved safety profiles, the method achieves effective gene delivery while maintaining cell survival and engraftment potential
Solution Approach 2:
The patent optimizes cell preparation and cultural conditions prior to transduction to enhance cell robustness and resistance to transduction stress. This preliminary conditioning allows the use of optimized MOI that achieves high transduction efficiency while preserving cell viability and functional capacity
Data Source
AI summary
The invention provides improved gene therapy methods and compositions. In particular embodiments, gene therapies comprise hematopoietic stem and progenitor cell compositions with increased therapeutic efficacy and methods of making and using the same. In other particular embodiments, the present invention contemplates compositions and methods for increasing transduction efficiency and vector copy number (VCN) of human hematopoietic stem and progenitor cells (HSPCs) to yield improved gene therapy compositions. In various embodiments, the present invention contemplates, in part, a population of HSPCs transduced with a lentiviral vector. In various embodiments, the present invention contemplates a method of treating sickle cell disease in a subject comprising administering the subject an effective amount of the population of hematopoietic cells contemplated herein. In various embodiments, the present invention contemplates a kit comprising an agent that increases prostaglandin EP receptor signaling and staurosporine.